ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

Ecuadorian scientists are developing a biotechnological strategy to stop banana wilt by genetically editing the causative ...

Overview of Autologous Cell Therapy Product MarketGlobal Cell Therapy Market is valued at USD 10.1 Billion in 2025 and is projected to attain a value of USD 16.1 Billion by 2030 at a CAGR of 12.10% ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

A U.S. biological research institute has developed a new genetic modification technique that promises a wide range of organism mutations while being safer than the ...

Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...

A leading bioethicist at Hiroshima University is calling for an anticipatory, rather than reactive, approach to ethics after ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.